SSY Group Secures Exclusive China License for OPT101, Novel Peritoneal Dialysis Therapy from Opterion Health
SSY Group Limited (HKG: 2005) announced it has entered into a letter of intent with...
SSY Group
SSY Group Limited Projected to Win 12 Products in China’s Eleventh VBP Round
China‑based SSY Group Limited (HKG: 2005) announced today that it has been pre‑selected as the...
HighTide Therapeutics and SSY Group Ltd Join Forces to Tackle Metabolic and Aging Diseases
China-based HighTide Therapeutics Inc. (HKG: 2511) has announced a strategic collaboration framework agreement with compatriot...
SSY Group Ltd Receives NMPA Approval for Stiripentol Dry Suspension for Dravet Syndrome
China-based SSY Group Ltd (HKG: 2005) has announced that it has received marketing approval from...
China Launches Eighth Round of National Volume-Based Procurement for 41 Drugs
The National Healthcare Security Administration has issued a notice to initiate the COVID-delayed eighth round...
SSY Group’s Blonanserin and Paracetamol Approved by China’s NMPA
China-based SSY Group Limited (HKG: 2005) has announced receiving market approvals from the National Medical...